Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) developing resistance to imatinib.

被引：0
|
作者：
Pfeifer, H
Wassmann, B
Pavlova, A
Mueller, M
Wunderle, L
Brueck, P
Oldenburg, J
Hochhaus, A
Gschaidmeier, H
Hoelzer, D
Ottmann, OG
机构：
[1] Univ Frankfurt, Dept Hematol, D-6000 Frankfurt, Germany
[2] Klinikum Mannheim, Med Klin 3, Mannheim, Germany
[3] Novartis Pharm, Nurnberg, Germany
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
147
引用
收藏
页码：46A / 47A
页数：2
相关论文
共 50 条
  • [1] Serial monitoring of BCR-ABL in newly diagnosed Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL) treated with imatinib.
    Lim, Sung-Nam
    Joo, Young-Don
    Kim, Ii-Hwan
    Lee, Won-Sik
    Lee, Sang Min
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
    Soverini, Simona
    Vitale, Antonella
    Poerio, Angela
    Gnani, Alessandra
    Colarossi, Sabrina
    Iacobucci, Ilaria
    Cimino, Giuseppe
    Elia, Loredana
    Lonetti, Annalisa
    Vignetti, Marco
    Paolini, Stefania
    Meloni, Giovanna
    di Maio, Valeria
    Papayannidis, Cristina
    Amabile, Marilina
    Guarini, Anna
    Baccarani, Michele
    Martinelli, Giovanni
    Foa, Robin
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (04): : 552 - 557
  • [3] ANALYSIS OF BCR-ABL KINASE DOMAIN MUTATIONS IN HUNGARIAN PATIENTS WITH IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA AND PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Nahajevszky, S.
    Barta, A.
    Lueff, S.
    Batai, A.
    Remenyi, P.
    Masszi, T.
    Fekete, S.
    Ujj, G.
    Tordai, A.
    Andrikovics, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 538 - 538
  • [4] Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Pfeifer, Heike
    Wassmann, Barbara
    Pavlova, Anna
    Wunderle, Lydia
    Oldenburg, Johannes
    Binckebanck, Anja
    Lange, Thoralf
    Hochhaus, Andreas
    Wystub, Silvia
    Brueck, Patrick
    Hoelzer, Dieter
    Ottmann, Oliver G.
    BLOOD, 2007, 110 (02) : 727 - 734
  • [5] Bcr-Abl tyrosine kinase domain mutations both pre-exist and develop during imatinib treatment and are responsible for resistance in patients with Philadelphia-Chromosome positive acute lymphoblastic leukemia (Ph plus ALL).
    Pfeifer, Heike
    Wassmann, Barbara
    Pavlova, Anna
    Wunderle, Lydia
    Brueck, Patrick
    Hochhaus, Andreas
    Hoelzer, Dieter
    Ottmann, Oliver
    BLOOD, 2006, 108 (11) : 192A - 193A
  • [6] BCR-ABL kinase domain mutations and resistance in Ph plus acute lymphoblastic leukemia from the imatinib to the second-generation TKI era
    Soverini, Simona
    Gnani, Alessandra
    De Benedittis, Caterina
    Iacobucci, Ilaria
    Venturi, Claudia
    Papayannidis, Cristina
    Luppi, Mario
    Merante, Serena
    Malagola, Michele
    Russo, Domenico
    Tiribelli, Mario
    Salvucci, Marzia
    Vitale, Antonella
    Elia, Loredana
    Vignetti, Marco
    Foa, Robin
    Baccarani, Michele
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] BCR-ABL kinase domain mutations in patient with secondary but not primary resistance to imatinib.
    Al-Ali, HK
    Lange, T
    Krahl, R
    Mueller, C
    Patzer, G
    Niederwieser, D
    Deininger, MWN
    BLOOD, 2002, 100 (11) : 368A - 369A
  • [8] Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Soverini, Simona
    Colarossi, Sabrina
    Gnani, Alessandra
    Castagnetti, Fausto
    Rosti, Gianantonio
    Bosi, Costanza
    Paolini, Stefania
    Rondoni, Michela
    Piccaluga, Pier Paolo
    Palandri, Francesca
    Giannoulia, Panagiota
    Marzocchi, Giulia
    Luatti, Simona
    Testoni, Nicoletta
    Iacobucci, Ilaria
    Cilloni, Daniela
    Saglio, Giuseppe
    Baccarani, Michele
    Martinelli, Giovanni
    HAEMATOLOGICA, 2007, 92 (03) : 401 - 404
  • [9] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [10] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Yuan Wei
    Mats Hardling
    Bob Olsson
    Rahil Hezaveh
    Anne Ricksten
    Dick Stockelberg
    Hans Wadenvik
    Annals of Hematology, 2006, 85 : 841 - 847
12345